CoChat

Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients

Open access

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index; 8 of the 20 sources its claims cite were checked for support.

Abstract

BACKGROUND: For extended-release drug formulations, effective half-life (t 1/2eff ) is a relevant pharmacokinetic parameter to inform dosing strategies and time to reach steady state. Tacrolimus, an immunosuppressant commonly used for the prophylaxis of organ rejection in transplant patients, is available as both immediate- and extended-release formulations. To the best of our knowledge, the t 1/2eff of tacrolimus from these different formulations has not yet been assessed. The objective of this study was to characterize the t 1/2eff and terminal half-life (t 1/2z ) of an extended-release once-daily tacrolimus formulation (LCPT) and twice-daily immediate-release tacrolimus (IR-Tac). METHODS: A noncompartmental analysis of pharmacokinetic data obtained from a phase 2 study in de novo kidney transplant recipients receiving either LCPT or IR-Tac was conducted. Intensive blood sampling was performed on days 1, 7, and 14, and tacrolimus whole blood concentrations were measured using a validated liquid chromatography with tandem mass spectrometry method. T 1/2eff was estimated using within-participant accumulation ratios. T 1/2z was estimated by linear regression of the terminal phase of the concentration versus time profile. RESULTS: The median accumulation ratios of LCPT and IR-Tac on day 14 were 3.18 and 2.06, respectively.The median (interquartile range; IQR) t 1/2eff for LCPT at day 14 of dosing was 48.4 (37.4-77.9) hours, whereas the t 1/2z was 20.3 (17.6-22.9) hours. For IR-Tac, the median (IQR) t 1/2eff and t 1/2z on day 14 were 12.5 (8.8-23.0) hours and 12.2 (9.2-15.7) hours, respectively. CONCLUSIONS: Consistent with its prolonged release of tacrolimus, LCPT demonstrated a higher accumulation ratio and a longer t 1/2eff compared with IR-Tac. These findings underscore the pharmacokinetic differences between different drug formulations of the same moiety and may help inform dose adjustments for LCPT in kidney transplantation.

Overview

CoChat Summary

TL;DR

This phase 2 pharmacokinetic analysis in de novo kidney transplant recipients found that once-daily LCPT tacrolimus accumulates more and has a much longer effective half-life than twice-daily immediate-release tacrolimus (IR-Tac). The authors conclude that effective half-life better reflects LCPT’s dosing behavior and may help guide dose adjustments in kidney transplantation.

Key findings

  • On day 14, the median accumulation ratio was higher with LCPT than IR-Tac: 3.18 vs 2.06.
  • For LCPT, median t1/2eff was 48.4 hours (IQR 37.4–77.9) on day 14, while median t1/2z was 20.3 hours (IQR 17.6–22.9).
  • For IR-Tac, median t1/2eff and t1/2z on day 14 were similar: 12.5 hours (IQR 8.8–23.0) and 12.2 hours (IQR 9.2–15.7), respectively.
  • Based on LCPT’s median t1/2eff of 48.4 hours, the paper estimates 8.1 days (IQR 6.2–13.0) to reach 93.75% of steady state.

Methods

  • Noncompartmental pharmacokinetic analysis of data from a phase 2, open-label, randomized study in adult de novo kidney transplant recipients assigned 1:1 to once-daily LCPT or twice-daily IR-Tac.
  • Intensive blood sampling on days 1, 7, and 14; tacrolimus whole-blood concentrations measured by validated LC-MS/MS.
  • t1/2eff estimated from within-participant accumulation ratios; t1/2z estimated by linear regression of the terminal phase of the concentration-time curve.

Limitations

  • The paper states the analysis was in de novo kidney transplant recipients, not stable kidney transplant recipients.
  • The phase 2 trial excluded patients with factors affecting tacrolimus pharmacokinetics (for example, interacting medications or liver dysfunction), and genotyping was not performed, so the impact of CYP3A4/5 polymorphisms could not be assessed.
  • The paper notes that clinician-driven dose changes meant some participants may not have been at steady state on day 7 or 14, which could have underestimated t1/2eff.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1097/ftd.0000000000001270

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1. LCPT dose-normalized exposure (AUC) and trough concentration (Cmin). Box plots display the 25th and 75th percentiles at the end of each box, with whiskers extending to the 10th and 90th percentiles. The horizontal lines within each box represent the median values.
FIGURE 1. LCPT dose-normalized exposure (AUC) and trough concentration (Cmin). Box plots display the 25th and 75th percentiles at the end of each box, with whiskers extending to the 10th and 90th percentiles. The horizontal lines within each box represent the median values.CC BY-NC-ND · PubMed Central
FIGURE 2. Estimated percentage of steady state achieved based on effective half-life (t1/2eff) for LCPT (top) and IR-Tac (bottom). Solid line represents the median, and the shaded area shows the interquartile range (25th–75th percentile).
FIGURE 2. Estimated percentage of steady state achieved based on effective half-life (t1/2eff) for LCPT (top) and IR-Tac (bottom). Solid line represents the median, and the shaded area shows the interquartile range (25th–75th percentile).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

4 Valid · 2 Not valid · 6 Not checked · 39 Own results and interpretations

27 more claims

Create a free account to see all 51 claims and to verify the 2 references still open.

See all claims — free account
  • It may state two separate claims as one. 10
  • Probably not a substantial claim. 13

Create a free account to see these claims.

Citations

Cites

Show all 13 references

Research works printed but not linked: 1

  1. Nigro, 2013, Improved bioavailability of MELTDOSE once-daily formulation of tacrolimus (LCP-Tacro) with controlled agglomeration allows for consistent absorption over 24 hrs: a scintigraphic and pharmacokinetic evaluation [abstract], Am J Transpl., 13, 335

Cited by

See all 3

Metadata

Authors
Momper, J. D., Venkataramanan, R., Jantz, A. S., Cibrik, D. M., Birdwell, K., Nguyen, T., Masters, B. M., & Patel, S. J.
Affiliations
  • University of California San Diego (US)
  • University of Pittsburgh (US)
  • Henry Ford Health (US)
  • The University of Kansas Health System (US)
  • Vanderbilt University Medical Center (US)
  • Veloxis Pharmaceuticals, Inc. (United States) (US)
Corresponding author
  • Momper, Jeremiah D.
  • Nguyen, Tk
Venue
Therapeutic Drug Monitoring
Published
2024-10-24
Volume
47
Issue
1
Pages
169-173
ISSN
  • 0163-4356 (ISSN-L)
  • 1536-3694
OpenAlex
W4403718850
Cited by
3
References
13
Citations by year
2026: 2 · 2025: 1
FWCI
1.28
Type
journal article
Language
en
Open access
Locations
  • Therapeutic Drug Monitoring (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords
tacrolimus, effective half-life, sustained-release formulation, immediate-release formulation, accumulation ratio, time to steady state, kidney transplantation, immunosuppression, pharmacokinetics, drug formulation comparison, dose adjustment, whole blood concentration, liquid chromatography-tandem mass spectrometry, non-compartmental analysis, rejection prophylaxis, drug release rate, dose proportionality, pharmacovigilance
MeSH terms
Administration, Oral, Adult, Aged, Delayed-Action Preparations, Female, Half-Life, Humans, Immunosuppressive Agents, Male, Middle Aged, Kidney Transplantation, Tacrolimus, Tandem Mass Spectrometry, Transplant Recipients

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients. https://app.cochat.ai/papers/10.1097/ftd.0000000000001270
The paper
Momper, J. D., Venkataramanan, R., Jantz, A. S., Cibrik, D. M., Birdwell, K., Nguyen, T., Masters, B. M., & Patel, S. J. (2025). Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients. Therapeutic Drug Monitoring. https://doi.org/10.1097/ftd.0000000000001270

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.